Breast, colorectal and skin cancer screening and early diagnosis with treatment provides economic value, while lung cancer screening and early diagnosis with treatment came close to providing economic value. Bladder, endometrial, kidney, leukemia, non-Hodgkin lymphoma, pancreatic, prostate and thyroid cancer screening and early diagnosis with treatment were not found to have provided economic value.